XBKK
SKR
Market cap466mUSD
Nov 12, Last price
7.70THB
Name
Sikarin PCL
Chart & performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Sikarin Public Company Limited, along with its subsidiaries, functions as a healthcare provider managing hospitals throughout Thailand. The company delivers a comprehensive range of medical services and facilities, encompassing specialized care units for diabetes, endocrine disorders, general medicine, orthopedics, emergency and trauma, various surgical procedures, pediatric care, dentistry, aesthetic treatments, women's health, and fertility. Furthermore, it houses dedicated centers for gastroenterology, neurology, stroke, EENT (Ear, Nose, and Throat), and an international medical center. Diagnostic and therapeutic capabilities are robust, featuring a full laboratory department, diagnostic radiology, CT scan and MRI units, multiple operating rooms, a hemodialysis unit, a physical therapy department staffed with rehabilitation specialists, and a catheter laboratory. Patient accommodation includes intensive care units (ICUs), a coronary care unit (CCU), delivery rooms, nurseries, and a variety of inpatient wards such as general, international, obstetrics and gynecology, after heart and thoracic surgery, medical, and pediatric wards. Beyond its core healthcare operations, Sikarin also oversees the management of rental properties and is involved in the sale of food and beverages. The company's hospital portfolio includes Sikarin Hospital in Bangkok, equipped with 355 beds; Rattarin Hospital in Muang, offering 100 beds; and Sikarin Hat-Yai Hospital in Hat Yai, providing 350 beds. Established in 1979, Sikarin Public Company Limited is headquartered in Bangkok, Thailand.
Key people
Seni Chittakasem
Independent Chairman of the Board · since 2015
Sakchai Thanaboonchai
Independent Vice Chairman of the Board · since 2009
Paweena Chanchanasopon
Chief Financial Officer · since 2024
Sucheep Boonveera
Executive Director, Director · since 2012
Atirat Charoonsri
Managing Director, Executive Director · since 2002
Suriyan Kojonroj
Chief Operating Officer, Deputy Managing Director, Executive Director, Company Secretary · since 2024
Senee Krajangsri
Executive Director, Senior Chief Officer · since 2024
Jarax Sangtaweep
Executive Vice Chairman of the Board, Chief Executive Officer · since 2024
Sanya Sarayut
Executive Vice Chairman of the Board · since 2009
Tim Noparumpa
Director · since 2014
Director · since 2016
Jarun Wiwatjesadawut
Director · since 2002
Kasidit Ajanant
Independent Director · since 2013
Independent Director · since 2015
Pramuanchai Taweesedt
Independent Director · since 2005
Nipat Wuttironarit
Independent Director · since 2020
Valuation
Title THB in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||